论文部分内容阅读
2005～2007年期间,美国临床试验注册中心的数据表明,由药企赞助的各治疗领域的药物临床试验中,增长最快的是风湿性疾病(157.6%),而药企对心脏疾病药物以及抗细菌感染药物的研发兴趣逐渐降低。
From 2005 to 2007, the data from the American Clinical Trial Register showed that the fastest-growing drug-clinical trials in various therapeutic fields sponsored by pharmaceutical companies were rheumatic diseases (157.6%), and pharmaceutical companies were more likely to have heart disease drugs and R & D interest in anti-bacterial drugs is gradually decreasing.